Iguratimod suppresses Tfh cell differentiation in primary Sjögren’s syndrome patients through inhibiting Akt/mTOR/STAT3 signaling

BACKGROUND: Iguratimod (IGU) reduces hypergammaglobulinemia and disease activity in pSS (primary Sjögren’s syndrome) patients. However, the therapeutical mechanism of IGU for pSS remains largely unknown. This study aimed to investigate the regulation of Tfh cell differentiation by IGU in pSS patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Taibiao, Jiang, Hui, Zeng, Liuting, Liu, Suying, He, Chengmei, Luo, Chaowen, Qiao, Lin, Zhao, Yan, Chen, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463648/
https://www.ncbi.nlm.nih.gov/pubmed/37608388
http://dx.doi.org/10.1186/s13075-023-03109-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463648/
https://www.ncbi.nlm.nih.gov/pubmed/37608388
http://dx.doi.org/10.1186/s13075-023-03109-4

Ejemplares similares